Dr Kelcey M Schaum, PSYD | |
1640 Skyview Ln, Bruceton Mills, WV 26525-6891 | |
(304) 379-5000 | |
Not Available |
Full Name | Dr Kelcey M Schaum |
---|---|
Gender | Female |
Speciality | Psychologist |
Location | 1640 Skyview Ln, Bruceton Mills, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518636174 | NPI | - | NPPES |
NONE | Other | NONE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | 0810007431 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Kelcey M Schaum, PSYD 405 Richard Harrison Way, Morgantown, WV 26501-1136 Ph: (724) 822-2592 | Dr Kelcey M Schaum, PSYD 1640 Skyview Ln, Bruceton Mills, WV 26525-6891 Ph: (304) 379-5000 |
News Archive
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.
Today Royal Philips Electronics launched its newest line of neonatal blood pressure solutions. As the global leader in neonatal monitoring, Philips designed the new line of neonatal cuffs, air hoses, and upgrade kits specifically to prevent tragic misconnection errors that can cause harm to the most vulnerable of patients.
In the early 1990s, an international effort was launched by the U.S. Department of Energy and the National Institutes of Health to sequence the human genome. The project took 13 years, involved many scientists in several countries, and cost $2.7 billion (in FY 1991) dollars.
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.
Spinal injuries are among the most disabling conditions affecting wounded members of the U.S. military. Yet until recently, the nature of those injuries had not been adequately explored.
› Verified 9 days ago
Dr. Kristine Brown, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1640 Sky View Drive, Bruceton Mills, WV 26525 Phone: 304-379-5127 |